Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL457592 | 0.84 | CYP11B1 (0.38) | ERN1CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL457853 | 0.81 | CYP2A6 (0.47) | ERN1SMN1; SMN2CYP2A6TTKNPY5R | |
| SCHEMBL457062 | 0.79 | TGFBR1 (0.38) | ERN1DHODH | |
| SCHEMBL15363840 | 0.79 | ERN1 (0.33) | ERN1CYP2A6CYP11B1CYP11B2DHODH | |
| SCHEMBL456610 | 0.78 | ERN1 (0.53) | ERN1SMN1; SMN2CYP11B1CYP11B2TTK | |
| SCHEMBL458722 | 0.77 | ERN1 (0.45) | ERN1SMN1; SMN2CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL16712516 | 0.77 | ERN1 (0.42) | ERN1SMN1; SMN2CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL456882 | 0.75 | CYP2C9 (0.43) | ERN1SMN1; SMN2CYP2A6TTKCYP2C9 | |
| SCHEMBL15363642 | 0.74 | CYP2A6 (0.35) | SMN1; SMN2CYP2A6CYP11B1CYP11B2NPY5R | |
| SCHEMBL456449 | 0.72 | CYP2A6 (0.51) | ERN1SMN1; SMN2CYP2A6CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614061-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-9029392-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2015-05-12 | — | — | US | disclosed |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-11-07 | — | — | US | disclosed |
| EP-2614061-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012032334-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | MAP3K13, MAP4K3, MAP3K3 | ERN1 713/4885SMN1; SMN2 3681/4885CYP2A6 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.